Trials / Terminated
TerminatedNCT03601819
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
Phase Ib, Open Label, Single Center Study of Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- University of Michigan Rogel Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial will determine the safety and tolerability of Pacritinib in patients with relapsed/refractory lymphoproliferative disorders.
Conditions
- Lymphoma, T-Cell, Cutaneous
- Lymphoma, T-Cell, Peripheral
- Chronic Lymphocytic Leukemia
- Lymphoproliferative Disorders
- Waldenstrom Macroglobulinemia
- Lymphoplasmacytic Lymphoma
- Mantle Cell Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pacritinib | Patients will receive continuous treatment until progressive disease, toxicity, or until any other condition for treatment discontinuation has been met. |
Timeline
- Start date
- 2019-05-15
- Primary completion
- 2020-03-07
- Completion
- 2020-07-17
- First posted
- 2018-07-26
- Last updated
- 2021-01-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03601819. Inclusion in this directory is not an endorsement.